disease.
48

Introduction
49
The neuroendocrine-immune network is a complex inter-regulatory system with wide 50 plasticity in order to maintain systemic homeostasis [1] [2] [3] . In females, the cyclic fluctuations in 51 the levels of gonadal hormones especially, 17β-estradiol affect the functioning of immune effector 52 cells by binding to specific receptors [4] [5] [6] [7] .
53
In the periphery, in vitro and in vivo 17β-estradiol-stimulation has been shown to enhance 54 splenocyte proliferation and cytokine production through the alteration of specific signaling to α1-/α2-or β1-/β2-/β3-adrenoceptors (AR) on lymphocytes and 17β-estradiol can bind to 66 cytosolic (cERs) or nuclear (nERs) 17β-estradiol receptors and initiate signals that target similar 67 down-stream signaling molecules, the underlying kinetic parameters will influence the outcome of the cross-talk through synergistic, additive or diminutive effects. Hence in this study, we have 69 created a dynamic model of resting lymphocyte functions in the presence of 17β-estradiol and/or 70 NE using kinetic principles that govern receptor-ligand activation from secondary data with 71 concentration and down-stream signaling data from in vitro studies published from our laboratory.
72
Also, in an attempt to understand the multiple levels of interactions between these two pathways, 73 we have also conducted docking studies of 17β-estradiol with the β2-AR and NE with the key 74 signaling molecule in 17β-estradiol signaling cascade p-ERK. 
Methods
76
Model building
77
The model was built using both primary and secondary data sources. neurotransmitter kinetics and at 24-72 hrs for long-term effects on lymphocyte functions.
88
Comparisons were drawn between in silico and in vitro data for validating the constructed model.
89
Sensitivity analysis was performed on key regulatory molecules to assess their individual impacts 90 on the dynamics of the system. Simulation of lymphocytes with adrenergic agonists terbutaline, clonidine, and 160 phenylephrine (Fig. 3A) , or 17β-estradiol (Fig. 3B) or both (Fig. 3C) agonists (Fig. 4C) . Stimulation with adrenergic agonists (Fig. 4A) , or with 17β-estradiol alone
172
( Fig. 4B ) or 17β-estradiol with adrenergic agonists (Fig. 4C ) significantly decreased peroxynitrite 173 production similarly. with clonidine (Fig. 8B) . to IFN-γ (3.5X10 -24 ) but not IL-2 production (Fig. 9A) . Similarly, signaling molecules also showed altered sensitivities upon stimulation with terbutaline, whereas p-ERK and p-CREB expression 204 alone showed increased sensitivity of 7X10 -21 (Fig. 9B) . There was a significant increase in the sensitivity of IFN-γ (3.5X10 -16 ) upon stimulation of 208 lymphocytes with 17β-estradiol (Fig. 10A) of 2Ȧand an energy of -5.02Kcal/mol (Fig. 11A) and to Asp 177 which is close to the catalytic 217 pocket with a Ki=365.7µM and an energy of -4.69Kcal/mol ( Fig. 11B and 11C ). 
Discussion
Immune functions of innate, humoral or cell-mediated origin are modulated by sympathetic 226 signals and circulating hormone levels during health and disease in a dose and receptor-type-227 dependent manner [1, 10, 12, 19] . In vitro studies from our laboratory have shown that adrenergic 228 stimulation through α1-, α2-or β2-ARs using specific agonists non-specifically inhibit 
238
In the present study, we have modeled these signaling pathways in silico using MATLAB
239
Simbiology toolbox. Due to difficulties in conducting the experiments using NE, the in vitro 240 studies were conducted using receptor-specific agonists and antagonists. While these experiments 241 are highly beneficial in elucidating the dose-dependent effects on specific adrenoceptor sub-types,
242
they cannot be considered as absolute indicators of NE-mediated effects. This is because when NE to incorporate cross-talks between these pathways by using common signaling molecule pools.
250
As expected, the simulation of lymphocytes with adrenergic agonists, phenylephrine, and CAT activities. It is possible that these signaling molecules play a regulatory role in the 269 expression and activity of these enzymes, thereby, exerting immunomodulatory effects [25, 26] .
270
In our model, adrenergic activation, 17β-estradiol treatment, and their co-treatment decrease superoxide formation but enhance peroxynitrites, although 17β-estradiol treatment or co-treatment increase IL-2 production, α2-and β2-AR activation did not alter both IFN-γ and IL-2 production. 
Figure 11
Norepinephrine inhibits catalytic and phosphate binding residues of ERK:
434
Norepinephrine inhibits ERK (PDB ID: 2ERK; Rattus rattus) by binding to the catalytic and 435 phosphate binding residues (A), and residues close to the catalytic pocket (B and C).
436
Figure 12
17β-estradiol inhibits β2-AR binding to key residues:17β-estradiol inhibitsβ2-AR
